The Therapeutic Discovery Project provided much-needed relief for emerging biotech companies  working on life-saving treatments and cures

With the overwhelming success of our recent Call for Sessions, next year’s BIO International Convention may be the best yet!

The Small Business Innovation Research Grants Program Provides Critical Support to Small Biotech Companies Working on Promising Innovations

BIO President and CEO Jim Greenwood congratulated the FDA and biopharmaceutical sponsors for making 35 novel new treatments available to patients in FY11.

Underlying the PDUFA V recommendations are the principles that a science-based, transparent, and well-managed review process that appropriately balances benefits and risks can enhance public trust and increase patient access to new medicines.

Genetic engineering is the direct manipulation of an organism's genes. Genetic engineering is different from traditional breeding, where the organism's genes are manipulated indirectly.

While the U.S. leads in the area of biotechnology, there is no guarantee this competitive edge will continue.

Where can you network and partner with 15,000+ industry leaders from 65 countries across the globe?

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

This week’s BIO China International Conference displayed a growing recognition of China’s emergence as a global leader in the biotech industry and discussions focused on how to navigate the opportunities and challenges that exist in the rapidly emerging market.

Since the development of the first vaccine by Edward Jenner in 1796, we have seen tremendous progress in our ability to prevent deadly childhood infections.

BIO China will address the challenges and opportunities associated with doing business in China

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

Got questions regarding the submission process? We’ve got the answers! Here are a few of the most frequently asked questions regarding submitting a proposal.

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

The buzz at BIO India hones in on the lack of clarity and consistency within the clinical trials process

A new paper in Science from BIO concludes that at this early stage of development, synthetic biology does not pose significant novel threats that are fundamentally different from those faced by the biotechnology industry. The regulatory framework that has been shaping recombinant DNA technology for the past 40 years is generally applicable and relevant.

The U.S. Food and Drug Administration (FDA) announced on August 26 that it will convene its Veterinary Medicine Advisory Committee (VMAC) to consider an application by BIO member AquaBounty technologies for its genetically engineered (GE) AquAdvantage Salmon.

During this period of tremendous growth in both the Indian economy and its healthcare sector, it is a critical time to capitalize on the biotech opportunities available within India.

Vigorous government support has played a key role in encouraging China’s development of a bio-based economy, especially in regard to biofuels. 

What event featured CNN’s Fareed Zakaria, Former DNC Chairman Howard Dean, Republic Strategist Karl Rove, Former British Prime Minister Tony Blair, and the heads of the largest pharmaceutical manufacturers in the world?

Genetic engineering of agricultural animals could be one of the most interesting and promising fields of biotechnology.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.